Clearmind Completes First Cohort in Alcohol Use Disorder Trial
Clearmind Medicine has completed dosing in the first cohort of its Phase I/IIa trial of CMND-100 for alcohol use...
Jon Napitupulu
SpyGlass Pharma’s Remarkable, Positive 36-Month IOL Results
SpyGlass Pharma reported a 37% mean intraocular pressure reduction at 36 months in its first-in-human study of the bimatoprost...
NEK7 Degrader MRT-8102 Shows Promise in Preclinical Data
Preclinical data presented at AHA 2025 show MRT-8102, an oral NEK7-directed molecular glue degrader, selectively degrades NEK7, suppresses NLRP3...
Telitacicept Hits Endpoint in Phase 3 IgA Nephropathy Trial
Telitacicept reduced the 24-hour urine protein-to-creatinine ratio by 58.9% at Week 39, compared with an 8.8% reduction on placebo...
CRISPR’s CTX310 Shows Positive Phase 1 Lipid-Lowering Data
At the highest dose in a Phase 1 trial of 15 adults with refractory dyslipidemia, a single intravenous course...
Bioversys’ Important BV100 Phase 2b Trial Gets Wellcome Fund
BV100 will advance to an open-label, randomized Phase 2b trial for carbapenem-resistant Acinetobacter baumannii infections, with 90 evaluable patients...
Medera Presents Promising New Heart Failure Gene Therapy Data
Interim results from Medera’s MUSIC-HFpEF Phase 1/2a study reported no gene therapy–related serious adverse events among 10 treated patients,...
Promising New Data on Wilson Disease from Monopar at AASLD
In the Phase 2 ALXN1840-WD-204 copper balance study in Wilson disease, tiomolybdate choline (ALXN1840) produced a rapid and sustained...
Pacira Finishes Enrollment for Phase 2 Knee Drug Study
Pacira has completed enrollment in Part A of its Phase 2 ASCEND trial of PCRX-201, a locally administered IL‑1Ra...
Replimune Spotlights Late-Breaking RP1 Data at SITC 2025
The objective response rate was 33.6%, with a median duration of response of 24.8 months, in anti–PD-1–refractory advanced melanoma...